KR101696002B1 - 재조합 ｒｓｖ 항원 - Google Patents

재조합 ｒｓｖ 항원 Download PDF

Info

Publication number
KR101696002B1
KR101696002B1 KR1020127001782A KR20127001782A KR101696002B1 KR 101696002 B1 KR101696002 B1 KR 101696002B1 KR 1020127001782 A KR1020127001782 A KR 1020127001782A KR 20127001782 A KR20127001782 A KR 20127001782A KR 101696002 B1 KR101696002 B1 KR 101696002B1
Authority
KR
South Korea
Prior art keywords
ser
lys
delete delete
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127001782A
Other languages
English (en)
Korean (ko)
Other versions
KR20120097472A (ko
Inventor
가이 장 마리 페르난드 피에르 바우독스
노르만드 블라이스
쏘냐 엘 씨와이알
패트릭 레아울트
쟝-루이 뤼엘
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42670494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101696002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20120097472A publication Critical patent/KR20120097472A/ko
Application granted granted Critical
Publication of KR101696002B1 publication Critical patent/KR101696002B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020127001782A 2009-06-24 2010-06-24 재조합 ｒｓｖ 항원 Expired - Fee Related KR101696002B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21996409P 2009-06-24 2009-06-24
US61/219,964 2009-06-24
US33456810P 2010-05-13 2010-05-13
US61/334,568 2010-05-13
PCT/EP2010/059008 WO2010149745A1 (en) 2009-06-24 2010-06-24 Recombinant rsv antigens

Publications (2)

Publication Number Publication Date
KR20120097472A KR20120097472A (ko) 2012-09-04
KR101696002B1 true KR101696002B1 (ko) 2017-01-13

Family

ID=42670494

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127001782A Expired - Fee Related KR101696002B1 (ko) 2009-06-24 2010-06-24 재조합 ｒｓｖ 항원

Country Status (29)

Country Link
US (1) US9492531B2 (cg-RX-API-DMAC10.html)
EP (1) EP2445526B1 (cg-RX-API-DMAC10.html)
JP (2) JP6062245B2 (cg-RX-API-DMAC10.html)
KR (1) KR101696002B1 (cg-RX-API-DMAC10.html)
CN (1) CN102481359B (cg-RX-API-DMAC10.html)
AU (2) AU2010264688A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI1015917A2 (cg-RX-API-DMAC10.html)
CA (1) CA2766211A1 (cg-RX-API-DMAC10.html)
CL (1) CL2011003273A1 (cg-RX-API-DMAC10.html)
CO (1) CO6480978A2 (cg-RX-API-DMAC10.html)
CR (1) CR20120025A (cg-RX-API-DMAC10.html)
CY (1) CY1117673T1 (cg-RX-API-DMAC10.html)
DK (1) DK2445526T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2011000389A (cg-RX-API-DMAC10.html)
EA (1) EA023054B1 (cg-RX-API-DMAC10.html)
ES (1) ES2583257T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20160798T1 (cg-RX-API-DMAC10.html)
HU (1) HUE028085T2 (cg-RX-API-DMAC10.html)
IL (1) IL217013B (cg-RX-API-DMAC10.html)
MA (1) MA33449B1 (cg-RX-API-DMAC10.html)
MX (1) MX2012000035A (cg-RX-API-DMAC10.html)
PE (1) PE20121541A1 (cg-RX-API-DMAC10.html)
PL (1) PL2445526T3 (cg-RX-API-DMAC10.html)
PT (1) PT2445526T (cg-RX-API-DMAC10.html)
SG (1) SG176829A1 (cg-RX-API-DMAC10.html)
SI (1) SI2445526T1 (cg-RX-API-DMAC10.html)
UA (1) UA111141C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010149745A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201109199B (cg-RX-API-DMAC10.html)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
ES2987238T3 (es) * 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
SG176807A1 (en) * 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
RS56748B1 (sr) * 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
CN102294027A (zh) * 2011-07-26 2011-12-28 昆明理工大学 一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法
US9463236B2 (en) 2011-08-29 2016-10-11 Tokushima University RSV mucosal vaccine
DK2750683T4 (da) * 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
CN102743750B (zh) * 2012-07-09 2013-11-20 江苏省农业科学院 一种复方免疫增强剂、禽用疫苗及其制备方法
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) * 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CN103204943B (zh) * 2013-03-20 2014-07-23 中国科学院武汉病毒研究所 呼吸道合胞病毒F蛋白与Fc的融合蛋白及其用途
MX2015013832A (es) * 2013-04-08 2016-06-10 Medimmune Llc Composicion de vacuna y metodo de uso.
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
SG11201600709TA (en) * 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
US9322037B2 (en) * 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
CN115960263A (zh) * 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
MX2018012094A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN107872643A (zh) * 2016-09-23 2018-04-03 伊姆西Ip控股有限责任公司 用于视频监控系统的故障恢复方法和装置
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP7356911B2 (ja) 2017-06-14 2023-10-05 ヴァイロメティックス アーゲー 呼吸器合胞体ウイルスに対する予防のための環状ペプチド
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
KR102700187B1 (ko) * 2017-09-29 2024-08-28 에스케이바이오사이언스(주) 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CA3091558A1 (en) * 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
PE20211469A1 (es) 2018-11-13 2021-08-05 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
CA3121724A1 (en) 2018-12-20 2020-06-25 Virometix Ag Lipopeptide building blocks and synthetic virus-like particles
WO2020175660A1 (ja) * 2019-02-28 2020-09-03 Ｋｍバイオロジクス株式会社 Ｒｓｖ ｆ／ｇキメラワクチン
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
JP7822149B2 (ja) 2020-10-02 2026-03-02 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN114685627A (zh) * 2020-12-28 2022-07-01 广州更新生物医药科技有限公司 一种预防呼吸道合胞病毒的rAAV载体疫苗
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
CN115772230A (zh) * 2022-07-18 2023-03-10 青岛硕景生物科技有限公司 一种rsv重组抗原、其制备方法及应用
KR20250054810A (ko) 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
CN120153078A (zh) 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
JP2026500218A (ja) 2022-12-11 2026-01-06 ファイザー・インク インフルエンザおよびｒｓｖに対する免疫原性組成物
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
US20260232787A1 (en) * 2023-03-17 2026-08-13 Westvac Biopharma Co., Ltd. Vaccine against respiratory syncytial virus infection
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025263563A1 (ja) * 2024-06-20 2025-12-26 Ｋｍバイオロジクス株式会社 ＲＳＶ ＦＧキメラｍＲＮＡワクチン
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026038177A1 (en) 2024-08-16 2026-02-19 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026148356A1 (en) 2025-01-06 2026-07-09 BioNTech SE Coronavirus and influenza immunogenic combinations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154456A2 (en) 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
WO1989005823A1 (en) 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
WO1994015968A1 (en) 1993-01-08 1994-07-21 The Upjohn Company Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
CA2302833C (en) 1997-09-19 2007-05-08 American Cyanamid Company Peptides derived from the attachment (g) protein of respiratory syncytial virus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
SK287073B6 (sk) 1998-06-30 2009-11-05 Om Pharma N-Acyldipeptidový derivát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
US20040161846A1 (en) * 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
EP1372706B1 (en) 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
DK1719511T3 (da) 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
FR2873378A1 (fr) 2004-07-23 2006-01-27 Pierre Fabre Medicament Sa Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques
GB0422439D0 (en) 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008061243A2 (en) * 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
EP2181121A4 (en) 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
US8563002B2 (en) * 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
KR20110045008A (ko) 2008-07-18 2011-05-03 아이디 바이오메디컬 코포레이션 오브 퀘벡 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154456A2 (en) 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nature, 2006, Vol.439, No.7072. pp38-44.
PNAS, August 2001. Vol. 98, No.17, pp9859-9864.
The Journal of General Virology, 2006, Vol.87. No.6. pp1649-1658.

Also Published As

Publication number Publication date
CA2766211A1 (en) 2010-12-29
BRPI1015917A2 (pt) 2019-08-27
AU2014203636A1 (en) 2014-07-31
IL217013A0 (en) 2012-02-29
AU2014203636C1 (en) 2017-02-09
UA111141C2 (uk) 2016-04-11
CO6480978A2 (es) 2012-07-16
HUE028085T2 (en) 2016-11-28
KR20120097472A (ko) 2012-09-04
DOP2011000389A (es) 2012-04-30
CN102481359B (zh) 2015-08-19
DK2445526T3 (en) 2016-06-27
HRP20160798T1 (hr) 2016-08-12
AU2010264688A1 (en) 2012-01-19
PL2445526T3 (pl) 2017-08-31
ES2583257T3 (es) 2016-09-20
CL2011003273A1 (es) 2012-10-19
EP2445526B1 (en) 2016-05-11
MA33449B1 (fr) 2012-07-03
PT2445526T (pt) 2016-08-16
SG176829A1 (en) 2012-01-30
EA201270063A1 (ru) 2012-07-30
EA023054B1 (ru) 2016-04-29
SI2445526T1 (sl) 2016-08-31
MX2012000035A (es) 2012-02-28
WO2010149745A1 (en) 2010-12-29
ZA201109199B (en) 2012-08-29
JP6062245B2 (ja) 2017-01-18
US20120093847A1 (en) 2012-04-19
PE20121541A1 (es) 2012-12-21
AU2014203636B2 (en) 2016-10-20
CR20120025A (es) 2012-05-28
CN102481359A (zh) 2012-05-30
JP2012530504A (ja) 2012-12-06
IL217013B (en) 2018-02-28
EP2445526A1 (en) 2012-05-02
CY1117673T1 (el) 2017-05-17
JP2016128457A (ja) 2016-07-14
US9492531B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
KR101617895B1 (ko) 재조합 ｒｓｖ 항원
US9492531B2 (en) Recombinant RSV vaccines
KR20120093811A (ko) 백신
US20160122398A1 (en) Recombinant rsv antigens
HK40091519A (en) Recombinant rsv antigens
HK40092189A (en) Recombinant rsv antigens
HK40083885A (en) Recombinant rsv antigens
HK40085221A (en) Recombinant rsv antigens

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200107

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200107